17.87
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
ARS Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - PrintWeekIndia
Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia
What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional
What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com
MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance
EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance
ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha
(SPRY) Technical Data - news.stocktradersdaily.com
ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest
ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest
Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com India
ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest
ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
High Growth Tech Stocks in US for June 2025 - simplywall.st
Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com India
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):